Radiopharmaceuticals in the Multi-Isotope Era | PET Is No Longer Only About F-18 FDG⚛️

2026-06-11

Diagnostic radiopharmaceuticals use targeted molecules labeled with positron- or single-photon-emitting isotopes to visualize lesions at the molecular level.

🏥 For a long time, when people talked about PET imaging, F-18 FDG was often the first thing that came to mind.

And for good reason.

As one of the most mature and widely used PET radiopharmaceuticals, F-18 FDG reflects glucose metabolism in tissues and cells. It plays an important role in tumor diagnosis, staging, treatment response assessment, as well as neurological and cardiovascular imaging.

In many ways, F-18 FDG has laid the foundation for modern clinical PET applications.

🔬 But with the development of precision medicine and molecular imaging, the value of PET is no longer limited to “seeing metabolism.”

More clinical and research needs are driving PET imaging toward broader application scenarios:

🔹 Target expression assessment

🔹 Patient selection

🔹 Antibody biodistribution studies

🔹 Drug evaluation

🔹 Treatment response prediction and follow-up

🔹 Early evaluation for theranostic applications

🧪 These new scenarios are creating demand for more diagnostic isotopes.

Beyond F-18, isotopes such as C-11, N-13, Ga-68, Cu-64, Zr-89, I-124, In-111, and Sc-44 are playing increasingly important roles in molecular imaging research and clinical translation.

Different isotopes have different half-lives, positron energies, labeling methods, and biodistribution compatibility, making them suitable for different diseases, targets, molecules, and clinical questions.

⚛️ PET is entering a multi-isotope era.

For upstream production platforms, this means moving beyond single-isotope supply toward more flexible and expandable capabilities.

Based on medical cyclotron platforms and liquid, gas, and solid target systems, LBT supports the production of multiple diagnostic isotopes, including F-18, C-11, N-13, Ga-68, Cu-64, Zr-89, I-124, In-111, and Sc-44 — helping nuclear medicine centers and radiopharmaceutical platforms prepare for broader diagnostic applications.